In this drug-target MR analysis, we assessed the effects of LLDs on lung cancer risk via six LLD targets (APOB, APOC3, HMGCR, LPL, NPC1L1, and PCSK9), comprising 12 lipid-lowering pathways. This evidence concerns the gene APOC3 and lung carcinoma.